What Is the Anavex Life Sciences Corp. (AVXL) Class Action Lawsuit About?

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Anavex securities between November 26, 2025, and August 28, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case.

What Does the Anavex Life Sciences Corp. Securities Class Action Allege?

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that:

  1. Anavex lacked adequate internal controls;
  2. Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling; and
  3. as a result, defendants’ statements about Anavex’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

What’s Next for Anavex Investors?

A class action lawsuit has already been filed. You may review a copy of the Complaint. You may also contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911. If you suffered a loss in Anavex you have until November 30, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.